Current Psychiatry Reports

, Volume 9, Issue 4, pp 325–328 | Cite as

Early intervention in schizophrenia: Current and future perspectives

  • Matcheri S. Keshavan
  • Ali Amirsadri


The last decade has witnessed an expanding interest in the concept of early intervention (El) in psychotic disorders, notably schizophrenia. This is supported by the well-established association between prolonged untreated illness duration and poor outcome, as well as some evidence of progressive neurobiological changes in the early course of schizophrenia, both in the prepsychotic and psychotic phases as evidenced by brain imaging studies in schizophrenia. Increasingly, mental health service systems around the world have been incorporating specialized El programs. Controlled effectiveness studies in recent years have yielded encouraging data. Several questions in regard to the timing, choice of interventions, and the populations most likely to benefit from Els still remain. More evidence-based data are needed to place the El models in schizophrenia on firm footing in order to effectively implement them in the resource-strapped community mental health service settings.


Untreated Psychosis Mental Health Service System Schizotypal Disorder Mental Health Service Setting Ogic Intervention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Perkins DO, Gu H, Boteva K, et al.: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162:1785–1804.PubMedCrossRefGoogle Scholar
  2. 2.
    Marshall M, Lewis S, Lockwood A, et al.: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005, 62:975–983.PubMedCrossRefGoogle Scholar
  3. 3.
    Thompson PM, Vidal C, Giedd JN, et al.: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001, 98:11650–11655.PubMedCrossRefGoogle Scholar
  4. 4.
    Pantelis C, Velakoulis D, McGorry PD, et al.: Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281–288.PubMedCrossRefGoogle Scholar
  5. 5.
    Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991, 17:325–351.PubMedGoogle Scholar
  6. 6.
    Yung AR, Phillips LJ, McGorry PD: Treating Schizophrenia in the Prodromal Stage. London: Taylor & Francis; 2004.Google Scholar
  7. 7.
    Yung AR, Yuen HP, Berger G, et al.: Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007 [Epub ahead of print].Google Scholar
  8. 8.
    Pukrop R, Schultze-Lutter F, Ruhrmann S, et al.: Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first-and multiple-episode schizophrenia. J Clin Exp Neuropsychol 2006, 28:1388–1407.PubMedCrossRefGoogle Scholar
  9. 9.
    McGorry PD, Hickie IB, Yung AR, et al.: Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40:616–622.PubMedCrossRefGoogle Scholar
  10. 10.
    Keefe RS, Seidman LJ, Christensen BK, et al.: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004, 161:985–995.PubMedCrossRefGoogle Scholar
  11. 11.
    McGorry PD, Yung AR, Phillips LJ, et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921–928.PubMedCrossRefGoogle Scholar
  12. 12.
    McGlashan TH, Zipursky RB, Perkins D, et al.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163:790–799.PubMedCrossRefGoogle Scholar
  13. 13.
    Nordentoft M, Thorup A, Petersen L, et al.: Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006, 83:29–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Morrison AP, French P, Walford L, et al.: Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004, 185:291–297.PubMedCrossRefGoogle Scholar
  15. 15.
    Cornblatt BA, Lencz T, Kane JM: Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001, 51:31–38.PubMedCrossRefGoogle Scholar
  16. 16.
    Ohlsen RI, O’Toole MS, Purvis RG, et al.: Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004, 14(Suppl 4):S445–S451.PubMedCrossRefGoogle Scholar
  17. 17.
    Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.PubMedCrossRefGoogle Scholar
  18. 18.
    Jones PB, Barnes TR, Davies L, et al.: Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079–1087.PubMedCrossRefGoogle Scholar
  19. 19.
    Hogarty GE, Flesher S, Ulrich R, et al.: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004, 61:866–876.PubMedCrossRefGoogle Scholar
  20. 20.
    Petersen L, Jeppesen P, Thorup A, et al.: A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005, 331:602.PubMedCrossRefGoogle Scholar
  21. 21.
    Linszen D, Dingemans P, Lenior M: Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 2001, 51:55–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Marshall M, Rathbone J: Early intervention for psychosis. Cochrane Database Syst Rev 2006, 4:CD004718.Google Scholar
  23. 23.
    Blyler CR: Commentary: Service system perspectives on early intervention research. Schizophr Bull 2003, 29:867–875.PubMedGoogle Scholar
  24. 24.
    Pelosi AJ, Birchwood M: Is early intervention for psychosis a waste of valuable resources? Br J Psychiatry 2003, 182:196–198.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral NeurosciencesWayne State UniversityDetroitUSA

Personalised recommendations